SCHEMBL5280349

SCHEMBL5280349

CCNc1cc(C)cc(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.50
RAPGEF4 Q8WZA2 1/20 0.42
HTT P42858 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MAPT P10636 5/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP3A4 P08684 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.37
TSHR P16473 2/20 0.36
ALDH1A1 P00352 2/20 0.36
RECQL P46063 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12840855 0.84 THRB (0.38) THRBRAPGEF4HTTNPSR1MAPT
SCHEMBL21635498 0.84 ALDH1A1 (0.50) THRBRAPGEF4HTTNPSR1MAPT
SCHEMBL10154713 0.84 THRB (0.38) THRBRAPGEF4HTTNPSR1MAPT
SCHEMBL12136032 0.84 RAPGEF4 (0.44) THRBRAPGEF4HTTNPSR1MAPT
SCHEMBL12852152 0.84 RAPGEF4 (0.44) THRBRAPGEF4HTTNPSR1MAPT
SCHEMBL21812073 0.84 THRB (0.38) THRBRAPGEF4HTTNPSR1MAPT
SCHEMBL12229096 0.82 MAPT (0.41) THRBMAPTPOLBCYP3A4TSHR
SCHEMBL14039103 0.80 THRB (0.40) THRBRAPGEF4HTTNPSR1MAPT
SCHEMBL16236818 0.80 POLB (0.42) THRBRAPGEF4MAPTPOLBSMN1; SMN2
SCHEMBL4740356 0.80 THRB (0.64) THRBRAPGEF4HTTNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
CN-107088414-B A kind of N- ethylization catalyst and its preparing the application in N-ethylaniline derivative 湖北新德晟材料科技有限公司 2019-09-10 CN disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 US disclosed
CN-107088414-A A kind of N ethylizations catalyst and its application in N MEA derivatives are prepared 武汉德晟生化科技有限公司 2017-08-25 CN disclosed
CN-103975003-B Carbon fiber forming blank, moulding material and carbon fibre reinforced composite 东丽株式会社 2017-07-28 CN disclosed
US-20160096819-A1 PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF BASF SE (DE) 2016-04-07 US disclosed
EP-2997020-A1 PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF BASF SE (DE) 2016-03-23 EP disclosed
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS ALIOS BIOPHARMA, INC. 2016-02-18 US disclosed
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS ALIOS BIOPHARMA, INC. 2016-02-18 US disclosed
WO-2016022464-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS ALIOS BIOPHARMA, INC. (US) 2016-02-11 WO disclosed
EP-0350166-B1 Polymer compositions NIPPON OIL CO LTD (JP) 1994-03-23 EP disclosed
US-5208274-A Mixing with magnesium oxide or hydroxide and azelaic acid, catechol, glyoxal, or salicylic acid BORDEN, INC. (US) 1993-05-04 US disclosed
US-5180795-A Anilines, Salicylamide, Sulfanilic Acid, Anilinesulfonic Acid BORDEN, INC. (US) 1993-01-19 US disclosed
US-5120472-A POLYMER COMPOSITIONS NIPPON OIL COMPANY (JP) 1992-06-09 US disclosed
EP-0469785-A2 Retarders for curing/hardening resole resins Borden, Inc. (US) 1992-02-05 EP disclosed
EP-0350166-A2 Polymer compositions NIPPON OIL CO., LTD. (JP) 1990-01-10 EP disclosed
EP-0035355-B1 MODIFIED ALUMINIUM HYDRIDES, THEIR PREPARATION AND THEIR USE IN REDUCING ACETYLNAPHTHALENE DERIVATIVES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-05-09 EP disclosed
US-4418218-A REDUCTION WITH LITHIUM ALUMINUM HYDRIDE AND N-SUBSTITUTED EPHEDRINE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-11-29 US disclosed
US-4338255-A Modified lithium aluminum hydrides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1982-07-06 US disclosed
EP-0035355-A2 Modified aluminium hydrides, their preparation and their use in reducing acetylnaphthalene derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 THRB 758/4885RAPGEF4 4132/4885HTT 1087/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 THRB 758/4885RAPGEF4 4132/4885HTT 1087/4885
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS MAVS, EIF2AK2, SARS1 THRB 1940/4885RAPGEF4 2492/4885HTT 4869/4885
US-20160096819-A1 PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF CA3, CA2, CA1 THRB 2898/4885RAPGEF4 1530/4885HTT 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.